Equity Details
Price & Market Data
Price: $16.35
Daily Change: -$0.01 / 0.06%
Daily Range: $16.35 - $16.67
Market Cap: $51,873,947,648
Daily Volume: 4,639,224
Performance Metrics
1 Week: -0.79%
1 Month: -7.86%
3 Months: -9.28%
6 Months: 20.20%
1 Year: 15.72%
YTD: 5.32%
About Takeda Pharmaceutical Company Limited (TAK)
Dive into the latest financial snapshot of Takeda Pharmaceutical Company Limited (TAK). With a current trading price of 16.35, the stock has experienced a daily shift of -$0.01 / 0.06%. The company's market capitalization stands impressively at 51,873,947,648. Track its year-to-date performance, which is at 5.32%, alongside its weekly, monthly, and yearly trends.
Company Details
Employees: 47455
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Japan
Details
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan.